ELOX · Eloxx Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| Sumit Aggarwal PRESIDENT AND CEO | ▲ Buy | Option Exercise | 1,672,756 Shares held | 2/28/2026 | View profile |
| Domicilium Real Estate Fund III LP 10% Owner | ▼ Sell | Other | 361,578 Shares held | 6/10/2026 | View profile |
| MODUR VIJAY HEAD OF R&D | ▼ Sell | Tax Withholding | 154,953 Shares held | 12/1/2021 | View profile |
| Geffken Daniel E. INTERIM CFO | ▲ Buy | Open Market | 50,000 Shares held | 11/29/2021 | View profile |
| Lindsay Androski President and CEO | ▲ Buy | Option Exercise | 15,750 Shares held | 1/24/2025 | View profile |
| Alan Edmund Walts | ▲ Buy | Option Exercise | 15,567 Shares held | 1/24/2026 | View profile |
| Steven D. Rubin Director | ▲ Buy | Option Exercise | 14,625 Shares held | 1/24/2026 | View profile |
| Coastlands Capital LP 10% Owner | ▼ Sell | Other | 0 Shares held | 5/27/2026 | View profile |
Transaction History
| Domicilium Real Estate Fund III LP | ▼ Sell | Other | 238,422 | — | 6/10/2026 |
| Domicilium Real Estate Fund III LP | ▼ Sell | Other | 361,578 | — | 6/10/2026 |
| Domicilium Real Estate Fund III LP | ▼ Sell | Other | 113,636 | $0 | 5/27/2026 |
| Coastlands Capital LP | ▼ Sell | Other | 1,250,000 | $0 | 5/27/2026 |
| Sumit Aggarwal | ▲ Buy | Option Exercise | 260,946 | $39K | 2/28/2026 |
| Steven D. Rubin | ▲ Buy | Option Exercise | 1,875 | — | 1/24/2026 |
| Sumit Aggarwal | ▲ Buy | Option Exercise | 15,000 | — | 1/24/2026 |
| Alan Edmund Walts | ▲ Buy | Option Exercise | 1,875 | — | 1/24/2026 |
| Sumit Aggarwal | ▲ Buy | Grant | 1,000,000 | $0 | 9/19/2025 |
| Sumit Aggarwal | ▲ Buy | Option Exercise | 196,880 | $20 | 8/14/2025 |
| Lindsay Androski | ▲ Buy | Option Exercise | 3,750 | $0 | 1/24/2025 |
| Alan Edmund Walts | ▲ Buy | Option Exercise | 3,750 | $0 | 1/24/2025 |
| Sumit Aggarwal | ▲ Buy | Option Exercise | 30,000 | $0 | 1/24/2025 |
| Steven D. Rubin | ▲ Buy | Option Exercise | 3,750 | $0 | 1/24/2025 |
| Alan Edmund Walts | ▲ Buy | Grant | 12,000 | $0 | 10/16/2024 |
| Lindsay Androski | ▲ Buy | Grant | 12,000 | $0 | 10/16/2024 |
| Steven D. Rubin | ▲ Buy | Grant | 12,000 | $0 | 10/16/2024 |
| Sumit Aggarwal | ▲ Buy | Grant | 165,000 | $0 | 10/16/2024 |
| Alan Edmund Walts | ▲ Buy | Option Exercise | 37,695 | $0 | 12/1/2021 |
| Sumit Aggarwal | ▲ Buy | Option Exercise | 279,158 | $0 | 12/1/2021 |
| Sumit Aggarwal | ▼ Sell | Tax Withholding | 81,933 | $59K | 12/1/2021 |
| MODUR VIJAY | ▼ Sell | Tax Withholding | 64,373 | $46K | 12/1/2021 |
| MODUR VIJAY | ▲ Buy | Option Exercise | 219,326 | $0 | 12/1/2021 |
| Geffken Daniel E. | ▲ Buy | Open Market | 50,000 | $36K | 11/29/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Eloxx Pharmaceuticals Included in Pre-Market Movers List
Eloxx Pharmaceuticals was featured in a recent roundup of healthcare stocks showing movement during Monday's pre-market session. The company currently trades with a low trailing P/E ratio of 5.3, which is significantly below the average analyst target price of $38.25. This inclusion highlights current market attention on the stock, though the specific drivers for the pre-market activity are not detailed in the provided report.
Eloxx Pharmaceuticals Included in Pre-Market Movers List. Eloxx Pharmaceuticals was featured in a recent roundup of healthcare stocks showing movement during Monday's pre-market session. The company currently trades with a low trailing P/E ratio of 5.3, which is significantly below the average analyst target price of $38.25. This inclusion highlights current market attention on the stock, though the specific drivers for the pre-market activity are not detailed in the provided report.